Skip to main content

Table 3 Cough frequency: Responder analysis

From: The P2X3 receptor antagonist filapixant in patients with refractory chronic cough: a randomized controlled trial

Dose

> 30% reduction from baseline

(complete 24-h interval)

> 50% reduction from baseline

(complete 24-h interval)

Estimate [%]

90% credible limits

Estimate [%]

90% credible limits

Placebo

18.0

(11.3; 27.4)

4.79

(2.68; 8.40)

20 mg

20.3

(11.9; 32.5)

5.91

(3.05; 11.1)

80 mg

28.7

(13.9; 49.9)

10.9

(4.48; 24.2)

150 mg

40.6

(16.7; 70.0)

21.1

(6.96; 48.8)

250 mg

59.3

(21.3; 88.7)

44.8

(12.7; 81.9)

  1. Total number of patients = 23